Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blinded trial

Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blinded trial

Abstract Ischemia-reperfusion injury (IRI) causes vascular endothelial dysfunction. Preclinical data suggest that the SGLT2 inhibitor dapagliflozin may protect against vascular IRI. This trial has investigated if oral treatment with dapagliflozin can mitigate the transient impairment of IRI-induced-...

Full description

Saved in:
Bibliographic Details
Main Authors: Martin Lutnik, Stefan Weisshaar, Brigitte Litschauer, Michaela Bayerle-Eder, Jan Niederdöckl, Michael Wolzt
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Ischemia
Vascular function
Ischemia reperfusion injury
SGLT2-inhibitor
Online Access:https://doi.org/10.1038/s41598-025-01405-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-01405-4

Similar Items